Lymphoma Clinical Trials in Perth, Western Australia
14 recruitingPerth, Western Australia, Australia
Showing 1–14 of 14 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled116 locationsNCT05139017
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled265 locationsNCT06191744
Recruiting
Phase 2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Canadian Cancer Trials Group84 enrolled18 locationsNCT05180097
Recruiting
Phase 1
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
LymphomaLymphoma, Non-Hodgkin
Treeline Biosciences, Inc.180 enrolled11 locationsNCT07082803
Recruiting
Phase 1
A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma
B-cell Non Hodgkin Lymphoma
Sanofi96 enrolled16 locationsNCT06392477
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502
Recruiting
Phase 1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+2 more
Iksuda Therapeutics Ltd.140 enrolled13 locationsNCT05365659
Recruiting
Phase 1
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals230 enrolled5 locationsNCT05824585
Recruiting
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
OsteosarcomaRecurrent LymphomaLymphoblastic Lymphoma+4 more
Children's Oncology Group420 enrolled79 locationsNCT01790152
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Non-Hodgkin LymphomaLymphomaLymphoma, Non-Hodgkin+4 more
Caribou Biosciences, Inc.72 enrolled38 locationsNCT04637763